354 related articles for article (PubMed ID: 32071146)
1. Mouse Models of Myeloid Malignancies.
Basheer F; Vassiliou G
Cold Spring Harb Perspect Med; 2021 Jan; 11(1):. PubMed ID: 32071146
[TBL] [Abstract][Full Text] [Related]
2. Clonal expansion and myeloid leukemia progression modeled by multiplex gene editing of murine hematopoietic progenitor cells.
Shi X; Kitano A; Jiang Y; Luu V; Hoegenauer KA; Nakada D
Exp Hematol; 2018 Aug; 64():33-44.e5. PubMed ID: 29751067
[TBL] [Abstract][Full Text] [Related]
3. Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing.
Heckl D; Kowalczyk MS; Yudovich D; Belizaire R; Puram RV; McConkey ME; Thielke A; Aster JC; Regev A; Ebert BL
Nat Biotechnol; 2014 Sep; 32(9):941-6. PubMed ID: 24952903
[TBL] [Abstract][Full Text] [Related]
4. Mosaic loss of chromosome Y promotes leukemogenesis and clonal hematopoiesis.
Zhang Q; Zhao L; Yang Y; Li S; Liu Y; Chen C
JCI Insight; 2022 Feb; 7(3):. PubMed ID: 35132955
[TBL] [Abstract][Full Text] [Related]
5. Multiplex CRISPR/Cas9-Based Genome Editing in Human Hematopoietic Stem Cells Models Clonal Hematopoiesis and Myeloid Neoplasia.
Tothova Z; Krill-Burger JM; Popova KD; Landers CC; Sievers QL; Yudovich D; Belizaire R; Aster JC; Morgan EA; Tsherniak A; Ebert BL
Cell Stem Cell; 2017 Oct; 21(4):547-555.e8. PubMed ID: 28985529
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in the application of induced pluripotent stem cell technology to the study of myeloid malignancies.
Tatwavedi D; Pellagatti A; Boultwood J
Adv Biol Regul; 2024 Jan; 91():100993. PubMed ID: 37827894
[TBL] [Abstract][Full Text] [Related]
7. Studying clonal evolution of myeloid malignancies using induced pluripotent stem cells.
Doulatov S; Papapetrou EP
Curr Opin Hematol; 2021 Jan; 28(1):50-56. PubMed ID: 33264225
[TBL] [Abstract][Full Text] [Related]
8. How predictive is the finding of clonal hematopoiesis for the development of myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML)?
Steensma DP
Best Pract Res Clin Haematol; 2021 Dec; 34(4):101327. PubMed ID: 34865699
[TBL] [Abstract][Full Text] [Related]
9. Sequential CRISPR gene editing in human iPSCs charts the clonal evolution of myeloid leukemia and identifies early disease targets.
Wang T; Pine AR; Kotini AG; Yuan H; Zamparo L; Starczynowski DT; Leslie C; Papapetrou EP
Cell Stem Cell; 2021 Jun; 28(6):1074-1089.e7. PubMed ID: 33571445
[TBL] [Abstract][Full Text] [Related]
10. Generation of heterozygous SAMD9 CRISPR/Cas9-edited iPSC line (ESi086-A-3), carrying p.I1567M mutation.
Pera J; Castaño J; Casamitjana J; Giorgetti A; Romero-Moya D
Stem Cell Res; 2022 Oct; 64():102906. PubMed ID: 36087523
[TBL] [Abstract][Full Text] [Related]
11. Germline ATG2B/GSKIP-containing 14q32 duplication predisposes to early clonal hematopoiesis leading to myeloid neoplasms.
Pegliasco J; Hirsch P; Marzac C; Isnard F; Meniane JC; Deswarte C; Pellet P; Lemaitre C; Leroy G; Rabadan Moraes G; Guermouche H; Schmaltz-Panneau B; Pasquier F; Colas C; Benusiglio PR; Bera O; Bourhis JH; Brissot E; Caron O; Chraibi S; Cony-Makhoul P; Delaunay-Darivon C; Lapusan S; de Fontbrune FS; Fuseau P; Najman A; Vainchenker W; Delhommeau F; Micol JB; Plo I; Bellanné-Chantelot C
Leukemia; 2022 Jan; 36(1):126-137. PubMed ID: 34172895
[TBL] [Abstract][Full Text] [Related]
12. Clonal evolution and hierarchy in myeloid malignancies.
Takahashi K; Tanaka T
Trends Cancer; 2023 Sep; 9(9):707-715. PubMed ID: 37302922
[TBL] [Abstract][Full Text] [Related]
13. In vivo CRISPR/Cas9 screening identifies Pbrm1 as a regulator of myeloid leukemia development in mice.
Li BE; Li GY; Cai W; Zhu Q; Seruggia D; Fujiwara Y; Vakoc CR; Orkin SH
Blood Adv; 2023 Sep; 7(18):5281-5293. PubMed ID: 37428871
[TBL] [Abstract][Full Text] [Related]
14.
Beauchamp EM; Leventhal M; Bernard E; Hoppe ER; Todisco G; Creignou M; Gallì A; Castellano CA; McConkey M; Tarun A; Wong W; Schenone M; Stanclift C; Tanenbaum B; Malolepsza E; Nilsson B; Bick AG; Weinstock JS; Miller M; Niroula A; Dunford A; Taylor-Weiner A; Wood T; Barbera A; Anand S; Psaty BM; Desai P; Cho MH; Johnson AD; Loos R; ; MacArthur DG; Lek M; ; Neuberg DS; Lage K; Carr SA; Hellstrom-Lindberg E; Malcovati L; Papaemmanuil E; Stewart C; Getz G; Bradley RK; Jaiswal S; Ebert BL
Blood Cancer Discov; 2021 Sep; 2(5):500-517. PubMed ID: 34568833
[TBL] [Abstract][Full Text] [Related]
15. Opposing effects of acute versus chronic inhibition of p53 on decitabine's efficacy in myeloid neoplasms.
Tamura M; Yonezawa T; Liu X; Asada S; Hayashi Y; Fukuyama T; Tanaka Y; Kitamura T; Goyama S
Sci Rep; 2019 Jun; 9(1):8171. PubMed ID: 31160638
[TBL] [Abstract][Full Text] [Related]
16. [TFH lymphoma and associated clonal hematopoiesis].
Nann D; Fend F; Quintanilla-Martinez L
Pathologie (Heidelb); 2023 Dec; 44(Suppl 3):144-149. PubMed ID: 37870568
[TBL] [Abstract][Full Text] [Related]
17. Aberrant histone modifications induced by mutant ASXL1 in myeloid neoplasms.
Asada S; Kitamura T
Int J Hematol; 2019 Aug; 110(2):179-186. PubMed ID: 30515738
[TBL] [Abstract][Full Text] [Related]
18. Clonal Hematopoiesis and therapy related MDS/AML.
Desai P; Roboz GJ
Best Pract Res Clin Haematol; 2019 Mar; 32(1):13-23. PubMed ID: 30927970
[TBL] [Abstract][Full Text] [Related]
19. Immune Dysregulation and Recurring Mutations in Myelodysplastic Syndromes Pathogenesis.
Matos A; Magalhães SMM; Rauh MJ
Adv Exp Med Biol; 2021; 1326():1-10. PubMed ID: 33385175
[TBL] [Abstract][Full Text] [Related]
20. Cytogenetics in benzene-associated myelodysplastic syndromes and acute myeloid leukemia: new insights into a disease continuum.
Irons RD; Kerzic PJ
Ann N Y Acad Sci; 2014 Mar; 1310():84-8. PubMed ID: 24611724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
